```html

Zollinger‑Ellison Syndrome (Type III) – A Patient‑Friendly Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more tumors called gastrin‑producing neuroendocrine tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which dramatically increases stomach acid production. The resulting hyper‑acidic environment can damage the lining of the stomach and small intestine, leading to severe peptic ulcers.

There are three recognized types of ZES:

• Type I: Associated with chronic autoimmune gastritis.
• Type II: Linked to multiple endocrine neoplasia type 1 (MEN‑1) syndrome.
• Type III: Sporadic, non‑MEN‑1, non‑autoimmune—this is the focus of this guide.

Who it affects

• Both sexes; slight male predominance (≈55 % male).
• Median age at diagnosis: 45–55 years, but cases range from teens to adults > 70 years.

Prevalence

ZES is extremely uncommon, occurring in roughly 1–3 cases per million people per year worldwide (Mayo Clinic, 2023). Type III accounts for approximately 25‑30 % of all ZES cases, making it the least common subtype.

Symptoms

Because excess gastric acid erodes the mucosa throughout the upper GI tract, symptoms can be broad and may mimic other ulcer‑related diseases. Below is a comprehensive list, grouped by organ system.

Gastrointestinal Symptoms

• Recurrent abdominal pain – often epigastric, worsens 1–3 h after meals.
• Chronic or intermittent heartburn – due to acid reflux.
• Severe acid‑related peptic ulcers – may be multiple, > 3 cm, or located beyond the duodenum (e.g., jejunal ulcers).
• Nausea & vomiting – can be projectile if obstruction from ulcer scar tissue occurs.
• Gastrointestinal bleeding – melena or hematemesis when ulcers erode blood vessels.
• Diarrhea – acidic chyme inactivates pancreatic enzymes, leading to malabsorption.
• Weight loss – from malabsorption, pain‑induced anorexia, or chronic vomiting.

Systemic Symptoms

• Fatigue – secondary to anemia from chronic GI bleeding.
• Iron‑deficiency anemia – low ferritin, microcytic RBCs.
• Electrolyte disturbances – especially low magnesium and potassium due to persistent diarrhea.

Symptoms Related to Tumor Mass Effect (Less Common)

• Feeling of fullness or a palpable abdominal mass.
• Back or flank pain if the tumor invades nearby structures.

Causes and Risk Factors

Primary Cause

Type III ZES is caused by **sporadic gastrinomas** that arise independently of known hereditary syndromes. These tumors originate from neuroendocrine (Kulchitsky) cells in the pancreas or duodenum and secrete gastrin autonomously.

Risk Factors

• Age – incidence rises after the fourth decade.
• Male sex – modestly higher risk.
• Smoking – nicotine may promote neuroendocrine tumor growth (American Cancer Society, 2022).
• Chronic gastritis or Helicobacter pylori infection – may predispose to mucosal injury, but does not directly cause type III ZES.
• Family history of neuroendocrine tumors – although type III is sporadic, a familial predisposition can raise suspicion.

Diagnosis

Diagnosing ZES requires **biochemical confirmation of hypergastrinemia** plus **evidence of gastric acid hypersecretion** and localization of the gastrinoma.

Step‑by‑Step Diagnostic Pathway

1. Clinical suspicion – recurrent, treatment‑resistant ulcers, especially distal to the duodenum.
2. Fasting serum gastrin level
   • Elevated > 1000 pg/mL (normal < 100 pg/mL) is highly suggestive.
   • Values 2–10× upper limit of normal with low gastric pH (< 2) also support diagnosis.
3. Secretin stimulation test (gold standard when gastrin is modestly elevated)
   • In ZES, serum gastrin paradoxically rises > 120 pg/mL after IV secretin.
4. Acid output measurement – basal acid output > 15 mEq/h or maximal acid output > 30 mEq/h confirms hypersecretion.
5. Imaging for tumor localization
   • Multiphasic contrast‑enhanced CT of abdomen/pelvis (sensitivity 70‑80 %).
   • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highest sensitivity (≈90 %).
   • Endoscopic ultrasound (EUS) – excellent for small pancreatic lesions (< 2 cm).
6. Endoscopic evaluation – Upper endoscopy (EGD) to document ulcer burden and rule out H. pylori.

Pathology

If a lesion is surgically removed, pathology confirms a well‑differentiated neuroendocrine tumor with immunohistochemical staining positive for gastrin, chromogranin A, and synaptophysin.

Treatment Options

Therapy aims to (1) control acid hypersecretion, (2) eradicate or control the gastrinoma, and (3) manage complications.

1. Acid‑Suppressive Medications

• High‑dose proton‑pump inhibitors (PPIs) – omeprazole 40–80 mg daily, esomeprazole 40 mg BID, or pantoprazole 80 mg BID. PPIs are the cornerstone; most patients achieve symptom control within days.
• H₂‑blockers (e.g., ranitidine) – less effective alone but may be added when PPIs are insufficient.
• Long‑term PPI therapy requires monitoring of serum magnesium, calcium, vitamin B12, and bone density (NIH, 2022).

2. Surgical Management

Curative surgery is possible in up to 70 % of type III patients because these tumors are often solitary and localized.

• Enucleation – for small (< 2 cm), well‑circumscribed lesions not involving major vessels.
• Pancreaticoduodenectomy (Whipple procedure) – when the tumor is in the pancreatic head or duodenum with involvement of surrounding tissue.
• Distal pancreatectomy – for lesions in the pancreatic body/tail.
• Lymphadenectomy – recommended because up to 30 % of sporadic gastrinomas have nodal metastases.

Post‑operative follow‑up includes serial gastrin levels and imaging every 6–12 months for at least 5 years.

3. Medical Therapies for Unresectable or Metastatic Disease

• Somatostatin analogs (octreotide LAR 30 mg IM q28 days or lanreotide) – decrease gastrin secretion and may stabilize tumor growth.
• Targeted therapy – Everolimus (mTOR inhibitor) approved for progressive neuroendocrine tumors.
• Cytotoxic chemotherapy – Streptozocin combined with 5‑fluorouracil or doxorubicin for high‑grade disease.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for tumors expressing somatostatin receptors (high response rates in metastatic NETs).

4. Lifestyle & Supportive Care

• Adopt a low‑acid diet – avoid very spicy foods, citrus, coffee, and carbonated beverages.
• Stay well‑hydrated – especially if on high‑dose PPIs.
• Supplement magnesium, calcium, and vitamin B12 as directed.
• Regular bone density scans (DEXA) every 2–3 years.

Living with Zollinger‑Ellison Syndrome (Type III)

Daily Management Tips

• Medication adherence – take PPIs exactly as prescribed; never skip doses.
• Monitor symptoms – keep a diary of pain episodes, heartburn, and bowel movements.
• Routine labs – every 6 months: fasting gastrin, CBC, CMP, magnesium, calcium, and vitamin B12.
• Nutrition – work with a dietitian experienced in high‑acid GI disorders; a moderate‑protein, low‑fat diet can reduce ulcer‑inducing stress.
• Physical activity – regular moderate exercise improves bone health and overall well‑being.
• Psychosocial support – join support groups (e.g., NET Patients Network) to share experiences and coping strategies.

Follow‑Up Schedule

Time Frame	Visit / Test
Every 3–6 months (first 2 years)	Clinical review, serum gastrin, CBC, CMP, PPI side‑effect assessment.
Annually	Upper endoscopy (if ulcer disease persists) and imaging (CT or Ga‑68 DOTATATE PET/CT).
Every 2–3 years	DEXA scan for bone density.

Prevention

Because type III ZES is sporadic, specific primary prevention is limited. However, general measures can reduce the overall risk of neuroendocrine tumors and ulcer complications:

• **Avoid tobacco** – smoking cessation lowers neuroendocrine tumor risk.
• **Limit alcohol** – excessive intake irritates the gastric mucosa.
• **Treat H. pylori infection** – eradication reduces background ulcer disease.
• **Maintain a healthy weight** – obesity is linked with increased gastric acid secretion.
• **Regular medical check‑ups** – early detection of unusual gastrointestinal symptoms leads to quicker work‑up.

Complications

If untreated or poorly controlled, ZES can lead to serious health problems:

• Perforated peptic ulcer – emergency surgery, risk of peritonitis.
• Gastrointestinal bleeding – may require endoscopic hemostasis or transfusion.
• Stricture formation – leading to gastric outlet obstruction.
• Malabsorption & chronic diarrhea – causing electrolyte imbalances and weight loss.
• Bone disease (osteoporosis/osteopenia) – long‑term acid suppression interferes with calcium absorption.
• Metastatic gastrinoma – liver, lymph nodes, or bone spread in ~30 % of sporadic cases.
• Secondary gastric carcinoids – rare but reported in prolonged severe hyperacidic states.

When to Seek Emergency Care

---

**Sources**: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Cancer Society, European Neuroendocrine Tumor Society (ENETS) Guidelines 2023, WHO Classification of Tumors of the Digestive System 2022, Cleveland Clinic. All information is intended for educational purposes and does not replace professional medical advice.

```